China Pharma Holdings (CPHI) Operating Margin (2010 - 2026)
China Pharma Holdings (CPHI) posted Operating Margin of 113.6% for Q1 2026, down 16.04% on a QoQ basis from 97.9% in Q4 2025, and down 4683.0% year-over-year from 2.48% in Q1 2025.
China Pharma Holdings (CPHI) Operating Margin (2010 - 2026) Analysis & Trends
China Pharma Holdings' Operating Margin history runs 17 years deep, the most recent figure standing at 113.6% for Q1 2026.
- Quarterly Operating Margin fell 4683.0% year-over-year to 113.6% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 90.13% (up 1303.0% YoY) and the FY2025 annual result came in at 78.16%, up 2317.0% from the prior year.
- Operating Margin was 113.6% for Q1 2026 at China Pharma Holdings, down from 97.9% in the prior quarter.
- Across five years, Operating Margin topped out at 20.28% in Q1 2023 and bottomed at 150.44% in Q2 2024.
- A 5-year average of 69.59% and a median of 63.57% in 2025 frame the typical range for Operating Margin.
- Annual changes were most pronounced in 2024 — Operating Margin plunged 10888 bps — and 2025, when it jumped 8687 bps.
- China Pharma Holdings' Operating Margin stood at 40.02% in 2022, then sank by 38 bps to 55.1% in 2023, then tumbled by 91 bps to 105.47% in 2024, then rose by 7 bps to 97.9% in 2025, then dropped by 16 bps to 113.6% in 2026.
- Business Quant data shows CPHI's Operating Margin at 113.6% in Q1 2026, 97.9% in Q4 2025, and 83.06% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 16.37% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 36.83% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -38.02% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 41.69% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -2.27% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 23.74% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.23% |
| 10 | China Pharma Holdings | 629,344.02 | 460,870.02 | 285,487.00 | -113.60% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -113.60% |
| Dec 31, 2025 | -97.90% |
| Sep 30, 2025 | -83.06% |
| Jun 30, 2025 | -63.57% |
| Mar 31, 2025 | -66.76% |
| Dec 31, 2024 | -105.47% |
| Sep 30, 2024 | -98.65% |
| Jun 30, 2024 | -150.44% |
| Mar 31, 2024 | -66.87% |
| Dec 31, 2023 | -55.10% |
| Sep 30, 2023 | -39.57% |
| Jun 30, 2023 | -41.56% |
| Mar 31, 2023 | -20.28% |
| Dec 31, 2022 | -40.02% |
| Sep 30, 2022 | -35.03% |
| Jun 30, 2022 | -48.33% |
| Mar 31, 2022 | -56.84% |
| Dec 31, 2021 | -22.45% |
| Sep 30, 2021 | -38.53% |
| Jun 30, 2021 | -31.17% |